These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 20817595)

  • 61. Acceptability and feasibility of a 12-week yoga vs. educational film program for the management of restless legs syndrome (RLS): study protocol for a randomized controlled trial.
    Selfe TK; Wen S; Sherman K; Klatt M; Innes KE
    Trials; 2019 Feb; 20(1):134. PubMed ID: 30770767
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Traditional Chinese medicine herbal preparations in restless legs syndrome (RLS) treatment: a review and probable first description of RLS in 1529.
    Yan X; Wang WD; Walters AS; Wang Q; Liu YJ; Chu FY
    Sleep Med Rev; 2012 Dec; 16(6):509-18. PubMed ID: 22459934
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Patients suffering from restless legs syndrome have low internal locus of control and poor psychological functioning compared to healthy controls.
    Brand S; Beck J; Hatzinger M; Holsboer-Trachsler E
    Neuropsychobiology; 2013; 68(1):51-8. PubMed ID: 23774053
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Review of quality of life instruments for the restless legs syndrome/Willis-Ekbom Disease (RLS/WED): critique and recommendations.
    Walters AS; Frauscher B; Allen R; Benes H; Chaudhuri KR; Garcia-Borreguero D; Lee HB; Picchietti DL; Trenkwalder C; Martinez-Martin P; Stebbins GT; Schrag A;
    J Clin Sleep Med; 2014 Dec; 10(12):1351-7. PubMed ID: 25348243
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Association of Restless Legs Syndrome With Risk of Suicide and Self-harm.
    Zhuang S; Na M; Winkelman JW; Ba D; Liu CF; Liu G; Gao X
    JAMA Netw Open; 2019 Aug; 2(8):e199966. PubMed ID: 31441941
    [TBL] [Abstract][Full Text] [Related]  

  • 66. ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.
    de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1365-80. PubMed ID: 25149093
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dopaminergic Augmentation in Restless Legs Syndrome/Willis-Ekbom Disease: Identification and Management.
    García-Borreguero D
    Sleep Med Clin; 2015 Sep; 10(3):287-92, xiii. PubMed ID: 26329438
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Restless legs syndrome and health-related quality of life in adults with multiple sclerosis.
    Cederberg KLJ; Jeng B; Sasaki JE; Braley TJ; Walters AS; Motl RW
    J Sleep Res; 2020 Jun; 29(3):e12880. PubMed ID: 31157499
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Poor effect of guideline based treatment of restless legs syndrome in clinical practice.
    Godau J; Spinnler N; Wevers AK; Trenkwalder C; Berg D
    J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1390-5. PubMed ID: 20884674
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Willis-Ekbom Disease Foundation revised consensus statement on the management of restless legs syndrome.
    Silber MH; Becker PM; Earley C; Garcia-Borreguero D; Ondo WG;
    Mayo Clin Proc; 2013 Sep; 88(9):977-86. PubMed ID: 24001490
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Possible sites of therapeutic action in restless legs syndrome: focus on dopamine and α2δ ligands.
    Thorpe AJ; Clair A; Hochman S; Clemens S
    Eur Neurol; 2011; 66(1):18-29. PubMed ID: 21709418
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effects of restless legs syndrome on quality of life and psychological status in patients with type 2 diabetes.
    Merlino G; Valente M; Serafini A; Fratticci L; Del Giudice A; Piani A; Noacco C; Gigli GL
    Diabetes Educ; 2010; 36(1):79-87. PubMed ID: 20185611
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Restless legs syndrome: a clinical update.
    Gamaldo CE; Earley CJ
    Chest; 2006 Nov; 130(5):1596-604. PubMed ID: 17099042
    [TBL] [Abstract][Full Text] [Related]  

  • 74. When restless legs syndrome turns malignant.
    Schulte EC; Gross N; Slawik H; Winkelmann J
    Sleep Med; 2013 Jun; 14(6):575-7. PubMed ID: 23643657
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Non-pharmacological interventions for restless legs syndrome: a systematic review of randomised controlled trials.
    Harrison EG; Keating JL; Morgan PE
    Disabil Rehabil; 2019 Aug; 41(17):2006-2014. PubMed ID: 29561180
    [No Abstract]   [Full Text] [Related]  

  • 76. Pharmacologic Treatment of Restless Legs Syndrome.
    Lv Q; Wang X; Asakawa T; Wang XP
    Curr Neuropharmacol; 2021; 19(3):372-382. PubMed ID: 33380302
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The relationship with iron and health outcomes in persons with restless legs syndrome.
    Cuellar NG; Hanlon A; Ratcliffe SJ
    Clin Nurs Res; 2011 May; 20(2):144-61. PubMed ID: 21041807
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Diagnosis, comorbidities, and management of restless legs syndrome.
    Becker PM; Novak M
    Curr Med Res Opin; 2014 Aug; 30(8):1441-60. PubMed ID: 24805265
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Contemporary challenges and strategies for improving outcomes for patients with restless legs syndrome.
    Buchfuhrer MJ
    Am J Manag Care; 2012 Nov; 18(12 Suppl):S283-90. PubMed ID: 23327482
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects.
    de Biase S; Merlino G; Valente M; Gigli GL
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1035-45. PubMed ID: 27310338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.